Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.1% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics Inc (NTLA): Intellia Therapeutics Inc is a clinical-stage gene editing company specializing in curative therapeutics using CRISPR/Cas9 technology for diseases with high unmet medical needs. The stock experienced significant bullish movement today.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 5.1% on Jan 8, 2026 15:00

• The surge in NTLA's stock price may be linked to notable insider purchasing activity by Director Fred Cohen, who acquired 150,000 shares of the company's common stock. This insider buy could have boosted market confidence in the company's future outlook.
• Contrasting Cohen's buying behavior with other insider transactions, which lean towards more sells than buys, might have indicated to investors that the director is optimistic about the company's long-term potential.
• Furthermore, anticipation surrounding the company's participation in the 44th Annual J.P. Morgan Healthcare Conference, where Intellia Therapeutics will discuss its CRISPR-based therapies, could have generated positive investor sentiment and contributed to the stock's bullish movement.
• Overall, a combination of insider buying activities, positive advancements in clinical trials, and involvement in a reputable healthcare conference likely fueled investor optimism, driving the upward momentum in NTLA's stock price.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Insider Buying: Fred Cohen Acquires 150,000 Shares of Intellia Therapeutics Inc (NTLA)

Fred Cohen, a Director at Intellia Therapeutics Inc (NTLA), recently purchased 150,000 shares of the company, bringing his total ownership to 207,453 shares. This transaction is part of a broader trend where Cohen has only bought shares, contrasting with other insider activities at NTLA which show more sells than buys. The stock is currently trading at $9.35, significantly below its GF Value of $23.94, suggesting it might be a "Possible Value Trap."

https://www.gurufocus.com/news/4100718/insider-buying-fred-cohen-acquires-150000-shares-of-intellia-therapeutics-inc-ntla

Intellia Therapeutics Insider Sold Shares Worth $314,485, According to a Recent SEC Filing

An insider at Intellia Therapeutics sold shares totaling $314,485, as reported in a recent SEC filing. This transaction follows other recent news for the company, including analyst rating adjustments and updates on its clinical trials. The company is focused on developing curative therapeutics using CRISPR/Cas9 technology for diseases with high unmet medical need.

https://www.marketscreener.com/news/intellia-therapeutics-insider-sold-shares-worth-314-485-according-to-a-recent-sec-filing-ce7e59dcd18bf625

Intellia Therapeutics, Inc. (NTLA) director purchases 150,000 shares

Intellia Therapeutics, Inc. director Fred E. Cohen reported an open market purchase of 150,000 shares of the company's common stock on January 5, 2026, at a weighted average price of $9.35 per share. These shares were acquired in multiple trades ranging from $9.13 to $9.68. Following this transaction, Cohen directly beneficially owns 207,453 shares of Intellia Therapeutics common stock.

https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-327186239651.html

Intellia Therapeutics Director Fred E Cohen Buys 150,000 Shares

Intellia Therapeutics Director Fred E Cohen purchased 150,000 shares of the company's common stock on January 5, 2026, for a total of $1,402,500 at $9.35 per share. Following this transaction, Cohen directly owns 207,453 shares of Intellia Therapeutics. This significant insider purchase highlights a director's increased stake in the company.

https://www.tradingview.com/news/tradingview:744d1c415d6a5:0-intellia-therapeutics-director-fred-e-cohen-buys-150-000-shares/

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Intellia Therapeutics, a clinical-stage gene editing company, announced its upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference. The company will discuss its work on CRISPR-based therapies, with a live webcast and replay available on its website. Intellia aims to advance medicine by leveraging gene editing technology to address unmet medical needs.

https://finance.yahoo.com/news/intellia-therapeutics-present-44th-annual-123000361.html

Trending Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Up 5.4% Today

PulteGroup Inc. ($PHM) Stock Forecast: Up 7.7% Today

Lennar Corporation Class A ($LEN) Stock Forecast: Up 8.6% Today

Intel Corporation ($INTC) Stock Forecast: Up 10.6% Today

Lam Research Corporation ($LRCX) Stock Forecast: Up 7.8% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.2% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Up 2.1% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Up 5.3% Today

Equity Residential of Beneficial Interest ($EQR) Stock Forecast: Down 4.5% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Up 6.0% Today

Intellia Therapeutics, Inc. Price History

06.00.2026 - NTLA Stock was up 6.3%

• The market sentiment towards NTLA has been negative due to a regulatory setback and FDA clinical hold on its main pipeline candidate, as well as mixed Q3 results.
• NTLA experienced a significant bullish movement today because of the inducement grants introduced by the company to recruit new talent.
• This action underscores Intellia's dedication to its goals and likely boosted investor confidence in the company's future, despite recent challenges.

28.09.2025 - NTLA Stock was down 6.8%

• The downward movement in NTLA stock could be tied to the overall negative sentiment in the biotechnology sector, possibly influenced by the recent downgrade of Boot Barn Holdings Inc. by a prominent Wall Street analyst.
• This shift in analyst perspective may have impacted investor trust in the sector, resulting in a sell-off of NTLA shares.
• Investors appear to be exercising caution regarding the future potential of gene editing technologies, including CRISPR/Cas9, in light of recent analyst actions and broader market patterns.

30.09.2025 - NTLA Stock was down 9.8%

• Intellia Therapeutics (NTLA) stock saw a significant drop in after-hours trading subsequent to the FDA's decision to place a clinical hold on some of its Investigational New Drug applications.
• The regulatory setback from the FDA has likely caused concerns among investors regarding potential delays in the company's drug development pipeline and its financial implications.
• This news prompted a sell-off as investors reassessed Intellia Therapeutics' short-term outlook, leading to a notable decrease in NTLA stock price.
• The bearish trend in NTLA stock may continue until there is more clarity on the FDA's issues and the company's plan to address them, underscoring the significance of regulatory risks in the biotech sector.

17.11.2025 - NTLA Stock was up 5.3%

• Marex Group plc acquired a noteworthy stake in NTLA in Q2, reflecting increasing investor confidence in the company's potential and future growth.
• Intellia Therapeutics exceeded Q3 earnings expectations, surpassing EPS estimates by $0.10, likely contributing to the positive market sentiment.
• Despite currently facing a class action lawsuit concerning securities fraud linked to the NTLA-3001 study, investors appear positive about the company's ability to tackle these legal challenges and concentrate on its innovative treatments.

08.00.2026 - NTLA Stock was up 5.1%

• The surge in NTLA's stock price may be linked to notable insider purchasing activity by Director Fred Cohen, who acquired 150,000 shares of the company's common stock. This insider buy could have boosted market confidence in the company's future outlook.
• Contrasting Cohen's buying behavior with other insider transactions, which lean towards more sells than buys, might have indicated to investors that the director is optimistic about the company's long-term potential.
• Furthermore, anticipation surrounding the company's participation in the 44th Annual J.P. Morgan Healthcare Conference, where Intellia Therapeutics will discuss its CRISPR-based therapies, could have generated positive investor sentiment and contributed to the stock's bullish movement.
• Overall, a combination of insider buying activities, positive advancements in clinical trials, and involvement in a reputable healthcare conference likely fueled investor optimism, driving the upward momentum in NTLA's stock price.

11.10.2025 - NTLA Stock was down 5.6%

• NTLA stock dropped despite posting a reduced loss in Q3, attributed to challenges in its pipeline and retracting guidance amidst FDA investigation in amyloidosis patients.
• Revenue for the quarter fell short of expectations, likely impacting investor sentiment negatively.
• Analysts revising their projections for the stock to a more pessimistic view also contributed to the decline in NTLA shares.
• Uncertainties related to the FDA investigation and the company's pipeline setbacks appeared to outweigh any positive aspects of the earnings report, resulting in a significant drop in stock price.

28.10.2025 - NTLA Stock was up 5.8%

• Intellia's bullish movement could be attributed to the positive advancements in its in vivo pipeline, particularly the progress in the HAELO study with lonvo-z.
• The comparison with a rival company might have sparked investor interest and confidence in Intellia's potential for long-term growth.
• The anticipation of mid-2026 data and a potential filing in the same year could have fueled optimism among investors, leading to the bullish market movement for NTLA today.

28.10.2025 - NTLA Stock was up 5.4%

• The bullish movement in NTLA could be attributed to the company's recent positive developments in its gene editing therapies, outshining its competitor BEAM.
• Investors might be favoring NTLA over BEAM due to its specific pipeline advancements and promising study results, leading to increased confidence in NTLA's potential for growth.
• This market movement suggests that NTLA's strategic positioning and progress in the gene editing sector are resonating well with investors, driving up the stock price significantly.

07.10.2025 - NTLA Stock was down 24.0%

• NTLA disclosed a Q3 loss and revenue estimates were not met, signifying financial underperformance.
• The adverse earnings surprise and revenue shortfall probably influenced investor apprehensions and the downward trend in the stock price.
• Investors might be wary about the company's future outlook and the implications of these financial outcomes on its pipeline and growth opportunities.

07.10.2025 - NTLA Stock was down 27.2%

• A recent decrease in Q3 losses did not prevent a significant bearish trend in NTLA stock. This was notably influenced by the company retracting guidance on a crucial pipeline milestone and encountering FDA scrutiny regarding amyloidosis patients.
• Despite the company's Q3 loss and revenue missing estimates, investor confidence dwindled further.
• Concerns over FDA scrutiny and uncertainty about the company's milestone achievements may have spurred a wave of sell-offs for NTLA stock.
• Investors are likely reassessing NTLA's future based on financial performance and regulatory obstacles, consequently amplifying the downward pressure on the stock price.

12.10.2025 - NTLA Stock was up 5.3%

• NTLA reported a narrowed Q3 loss, but the stock declined after the company withdrew guidance on a key pipeline milestone, sparking concerns about FDA scrutiny in amyloidosis patients.
• The company fell short of revenue expectations for the quarter, which may have initially contributed to negative market sentiment.
• Despite these setbacks, investors have responded positively to the progress and potential of NTLA's CRISPR-based therapies, driving the stock's upward movement today.
• The market appears to be reevaluating Intellia Therapeutics' long-term outlook, taking into account the potential impact of their innovative genetic disease treatments despite short-term challenges.

14.10.2025 - NTLA Stock was down 5.4%

• The company is currently dealing with FDA clinical holds on significant studies, causing uncertainty and negative sentiment among investors.
• Setbacks in the pipeline, particularly in ATTR studies, have raised concerns about Intellia's short-term outlook.
• The delay in crucial data concerning HAE treatment (lonvo-z) has contributed to the downward trend in NTLA stock.
• Regulatory challenges and uncertainties surrounding key data releases have fueled the substantial bearish movement in NTLA stock today.